AbbVie lifts annual profit forecast on resilient demand for newer immunology drugs

Core Insights - AbbVie raised its 2025 profit forecast due to strong sales of newer immunology drugs Skyrizi and Rinvoq, which contributed to third-quarter results exceeding Wall Street estimates [1] Company Performance - The strong performance in the third quarter was primarily driven by the sales of Skyrizi and Rinvoq, indicating a positive trend in AbbVie's product portfolio [1]